Official Title
Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2
Brief Summary

The purpose of this open label, 2-phase, study is to obtain information on the safety of 80 ppm and the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by SARS-CoV-2.

Not yet recruiting
COVID-19
SARS-CoV 2
Respiratory Disease
Pneumonia, Viral
Corona Virus Infection

Combination Product: 150 ppm Nitric Oxide delivered through LungFit Delivery System
Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 150 ppm for 40 minutes 4 time per day plus standard supportive care.
Phase 2- Group 1- Nitric oxide treatment- 150ppm

Combination Product: 80 ppm Nitric Oxide delivered through LungFit Delivery System
Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 80 ppm for 40 minutes 4 time per day plus standard supportive care.
Phase 1- Nitric oxide treatment- 80ppm

Eligibility Criteria

Inclusion Criteria: 1. Patients (male and female) admitted to the hospital for COVID-19 2. Patients with oxygen saturation less than 93 % on room air 3. Shortness of breath, with symptom onset within the previous 8 days. 4. Ability to understand and comply with study requirements . 5. Signed informed consent by subject

Exclusion Criteria: 1. Patients who are treated with or require high flow nasal cannula, CPAP, intubation, mechanical ventilation, or tracheostomy 2. Diagnosis of acute respiratory distress syndrome 3. Breastfeeding or pregnancy as evidenced by a positive pregnancy test. 4. Subjects diagnosed with immunodeficiency, with history of congestive or unstable heart disease, left ventricular dysfunction (LVEF 1 episode/month). 6. Significant hemoptysis during the last 30 days prior to enrollment 7. Methemoglobin level >3% at screening 8. Patients on systemic steroids (any formulation) within 30 days prior to enrollment. 9. History of daily, continuous oxygen supplementation

10. Patients with BMI greater than or equal to 36

11. Patient receiving drugs that have a contraindication with NO,

12. Patients with clinically significant anemia, e.g., Hb

Eligibility Gender
All
Eligibility Age
Minimum: 22 Years~Maximum: 75 Years
Contacts

Rinat Kalaora
+972-54-4750887
rkalaora@beyondair.net

Meital Hatan
+972-52-3215515
mhatan@beyondair.net

Asher Tal, MD
Study Director
Beyond Air

Beyond Air Inc.
NCT Number
MeSH Terms
Coronavirus Infections
Severe Acute Respiratory Syndrome
Pneumonia, Viral
Pneumonia
Respiration Disorders
Respiratory Tract Diseases
Nitric Oxide